A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Cipargamin (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Nov 2019 Planned number of patients changed from 150 to 210.
- 23 Aug 2019 Planned End Date changed from 19 Aug 2019 to 30 Apr 2020.
- 23 Aug 2019 Planned primary completion date changed from 13 May 2019 to 30 Apr 2020.